Most recent Article
Goodbody Botanicals secures significant product listing with WH Smith Travel (20 February 2020)
Goodbody Botanicals, has secured a CBD product listing agreement with WH Smith Travel Ltd (“WHS Travel”) which operates more than 550 UK convenience retail outlets with a concentration on travel hubs including airports, train stations, service stations and hospitals. Read more…

Latest articles

PRESS RELEASE: Placing and subscription to raise approximately £1.38 million

Sativa Group plc [NEX: SATI], the UK’s leading quoted CBD wellness and medicinal cannabis group, is pleased to announce that it has raised approximately £1.38 million (before expenses) by way of a placing and subscription of 34,500,000 new ordinary shares of 0.25 pence each (“New Ordinary Shares”) at a price of 4 pence per New Ordinary Share (the “Placing Price”) (the “Fundraising”).

PRESS RELEASE: Company Update (25th November 2019)

Following the appointment of Henry Lees-Buckley as Chief Executive Officer in August 2019, the Group has developed to become a UK-centric, cohesive and complementary group of five operating subsidiaries.

PRESS RELEASE: PDMR Shareholding (11th November 2019)

Sativa Group plc (NEX: SATI) has been notified that on 8 November 2019, George Thomas, MD of George Botanicals and a PDMR, completed the purchase of 500,000 ordinary shares of 0.25 pence each in the Company (“Ordinary Shares”) at an average price of 5.375p per share.

PRESS RELEASE: Home Office Grants Sativa a Controlled Drug Licence (16th October 2019)

Sativa Group Plc (NEX: SATI), the UK’s leading quoted CBD wellness and medicinal cannabis Group, is pleased to announce that its wholly owned subsidiary, Sativa Cultivation and Extraction Ltd, has been awarded a Controlled Drug licence for cannabis (with THC content of greater than 0.2%) cultivation, production, possession and supply, at its Somerset headquarters, by the UK Home Office.